CI

At a glance

ClinicalIndex Comparison Record
Phase 3Completed· 223 enrolled
Drug / intervention
Tenecteplasedrug
Likely dose
Tenecteplase 2 mLfrom record
Structured eligibility isn't available for this trial yet — see the full criteria in the Eligibility tab below.

Standardized by ClinicalIndex from the ClinicalTrials.gov record · verify against the source.

Search/NCT00396253
NCT00396253Phase 3Completed
CompareCT.gov

A Phase III, Open-Label Study of Tenecteplase for Restoration of Function in Dysfunctional Hemodialysis (HD) Catheters

Genentech, Inc.·interventional·Posted Nov 6, 2006·Updated Jan 12, 2017

In Brief

A Phase 3 clinical trial evaluating Tenecteplase for Dysfunctional Hemodialysis Catheters. Completed, enrolled 223 participants.

Detailed Summary

This was a Phase III, open-label study conducted at 44 centers in the United States, Canada, and Puerto Rico. 223 subjects who required hemodialysis (HD) and had a dysfunctional HD catheter were enrolled in the study.

Study Details

Study Typeinterventional
Allocation--
Masking--
Primary Purpose--
ConditionsDysfunctional Hemodialysis Catheters
Countries--
Collaborators--

Timeline

Phase 3CompletedFinished
200720082009201020112012201320142015201620172018201920202021202220232024202520262027
First PostedNov 6, 2006
Enrollment StartNov 1, 2006
Primary CompletionOct 1, 2008
TodayJul 2, 2026
Enrollment to primary: 1.9 yearsPosted 19.7 years ago

Interventions

Tenecteplasedrug

2 mL (2 mg) of reconstituted lyophilized tenecteplase instilled into each lumen of the HD catheter.